Effect of pravastatin on outcomes after cardiac transplantation

New England Journal of Medicine

Volumn 333, Issue 10, 1995, Pages 621-627

  Kobashigawa, Jon A ^a   Katznelson, Steven ^a   Laks, Hillel ^a   Johnson, Jay A ^a   Yeatman, Lawrence ^a   Wang, Xiu Ming ^a   Chia, David ^a   Terasaki, Paul I ^a   Sabad, Alejandro ^a   Cogert, Gregory A ^a   Trosian, Kevin ^a   Hamilton, Michele A ^a   Moriguchi, Jaime D ^a   Kawata, Nobuyuki ^a   Hage, Antoine ^a   Drinkwater, Davis C ^a   Stevenson, Lynne W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CHOLESTEROL; CORONARY DISEASE; CORONARY VESSELS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; SURVIVAL RATE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0029119711     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199509073331003     Document Type: Article

References (25)

1. Miller LW, Schlant RC, Kobashigawa JA, Kubo S, Renlund DG 24th Bethesda Conference: cardiac transplantation -- Task Force 5: complications. J Am Coll Cardiol 1993; 22: 41-54
2. Eich D, Thompson JA, Ko DJ, Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991; 10: 45-49
3. Sharples LD, Caine N, Mullins P, Risk factor analysis for the major hazards following heart transplantation -- rejection, infection, and coronary occlusive disease. Transplantation 1991; 52: 244-252
4. Gao SZ, Schroeder JS, Hunt S, Stinson EB Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 1988; 62: 876-881
5. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-3023
6. Brown G, Albers JJ, Fisher LD, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298
7. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-3012
8. Blankenhorn DH, Hodis HN Atherosclerosis -- reversal with therapy. West J Med 1993; 159: 172-179
9. Meiser BM, Wenke K, Thiery J, Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993; 25: 2077-2079
10. Cutts JL, Scallen TJ, Watson J, Bankhurst AD Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550-557
11. Cutts JL, Bankhurst AD Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990; 145: 244-252
12. Corpier CL, Jones PH, Suki WN, Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239-241
13. Kobashigawa JA, Murphy FL, Stevenson LW, Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82: Suppl IV: IV-281
14. Yoshimura N, Oka T, Okamoto M, Ohmori Y The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94-99
15. Wang XM, Terasaki PI, Rankin GW Jr, Chia D, Zhong HP, Hardy S A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol 1993; 37: 264-270
16. Ensley RD, Hammond EH, Renlund DG, Clinical manifestations of vascular rejection in cardiac transplantation. Transplant Proc 1991; 23: 1130-1132
17. Hammond EH, Yowell RL, Price GD, Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 1992; 11: S111-S119
18. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031-1037
19. Lin H, Wilson JW, Kendall TJ, Comparable proximal and distal severity of intimal thickening and size of epicardial coronary arteries in transplant arteriopathy of human cardiac allografts. J Heart Lung Transplant 1994; 13: 824-833
20. Doyle JW, Kandutsch AA Requirement for mevalonate in cycling cells: quantitative and temporal aspects. J Cell Physiol 1988; 137: 133-140
21. Kruezer J, Bader J, Jahn L, Hautmann M, Kubler W, Von Hodenberg E Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203-209
22. Linna J, Moke M, Chen HW. Isoprenoid formation and cell-mediated immunological functions. In: Friedman H, Specter S, Klein TW, eds. Drugs of abuse, immunity and immunodeficiency. Vol. 288 of Advances in experimental medicine and biology. New York: Plenum Press, 1991:269-78.
23. Totterman TH, Hanas E, Bergstrom R, Larsson E, Tufveson G Immunologic diagnosis of kidney-rejection using FACS analysis of graft-infiltrating functional and activated T and NK cell subsets. Transplantation 1989; 47: 817-823
24. Kirby JA, Givan AL, Shenton BK, Renal allograft rejection: possible involvement of antibody-dependent cell-mediated cytotoxicity. Transplantation 1990; 50: 225-229
25. McPherson R, Tsoukas C, Baines MG, Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439-444